Genomma Lab Intl Sab Ord

Good day, ladies and gentlemen. Thank you for joining Genoma Lab's third quarter, 2026 earnings conference call. All participants will be in listen-only mode. After today's presentation, there will be an opportunity to ask questions. As a reminder, this meeting is being recorded and will be available for replay from the investor relations section of Genoma's website following the call. I'll now turn the call over to Christianne Ibáñez, Genoma's Head of Investor Relations. Please, go ahead.

Thank you, Daniel, and welcome everyone. On today's call are Marco Sparvieri, Chief Executive Officer, and Antonio Zamora, Chief Financial Officer. Before we get started, I'd like to remind you that the remarks today will include forward-looking statements, Such as the company's financial guidance and expectations, including long-term objectives and forecasts, as well as expectations regarding Genoma's business, products, strategies, demands, and markets. These statements are subject to risks and uncertainties that could cause actual results to differ materially. They are also based on assumptions as of today, and the company undertakes no obligation to update them as a result of new information or future events. Let me now turn the call over to Mr. Marcos Sparvieri.

Thank you, Grace, and thank you everyone for joining our third quarter 2026 earnings call. Let me open with a quarter highlight. First, our recovery plan is reversing the trend as we anticipated. Mexico improved for a third quarter consecutive. Sellout returns to growth. and Market Share East Recovery, with Xerox reaching a historic high at the leading retailer. Second, EBITDA margin reached 21% in line with our expectations. This reflects our deliberate decision to invest more in the business in promotional activity and commercial spending to accelerate growth. And third, net margin expanded 168 basis points and Net Profit Group, 18.6%, driven by lower financial expenses and unfavorable foreign exchange results. Last quarter, we told you we expected a continued gradual recovery during the second half of 2026.